OZ Biosciences ads

Many primary and suspension cells remain non-permissive to viral infection. Pushing a higher MOI to compensate is costly and raises the immune response. This is why we have developed ViroMag, ViroMag R/L and AdenoMag, based on our Magnetofection™ technology: magnetic nanoparticle complexes that concentrate the viral dose at the cell surface and synchronize cell adsorption and infection, without modifying the virus. Compared to polybrene, magnetofection improved HIV-GFP transduction in NIH-3T3 cells while limiting toxicity. The same technology can also target transduction in vivo, for the targeted infection of diverse cell types. Transduction enhancement is only one step. We also offer solutions for virus production, capture and concentration. ➡️ Pick the enhancer that best fits your workflow: explore full protocol and data on our website.

Looking to optimize your viral workflow? Join us on October 15 to explore our different solutions covering virus production, capture and concentration, and transduction enhancement, from research use to GMP. ➡️ Register now: https://lnkd.in/dXBEjRm2 We look forward to seeing you there!

Third-generation lentiviral systems require co-transfecting up to four plasmids at a precise ratio, which makes reaching high functional titers difficult. This is why we have developed HYVIR, a lipid-based transfection kit designed for viral particle production in HEK-293T cells. Its formulation allows optimal plasmid compaction, protection and delivery, enabling efficient co-transfection and allows low DNA input. In a side-by-side comparison, particles produced with HYVIR transduced more cells and produced higher gene expression than particles produced with a standard transfection reagent. Production is only the first step. We also offer solutions for capture, concentration and transduction enhancement. ➡️ Pick the enhancer that best fits your workflow: contact us to request a sample.

Many primary and suspension cells remain non-permissive to viral infection, and pushing a higher MOI to compensate is costly and raises the immune response. This is why we offer LentiBlast Premium and AAVBlast, two patented chemical compositions that increase transduction efficiency across cell types without compromising cell viability. • LentiBlast Premium, a lentiviral transduction reagent, induces a higher fold increase in transduction than competing enhancers on CD34+ cells, even at low MOI, and is referenced in over 110 publications. • AAVBlast, an AVV transduction reagent, increases the transduction of AAV viral particles in HEK293 and Vero cell lines, across a wide range of cell types and serotypes. Transduction enhancement is only one step. We also offer solutions for virus production, capture and concentration. ➡️ Pick the enhancer that best fits your workflow: contact us to request a sample.

A complete and comprehensive toolbox for viral vectors: we offer a set of reagents that supports you at every step, from producing your virus to increasing transduction into your target cells. Viral workflows come with their own technical challenges. Reaching high functional titers requires co-transfecting multiple plasmids at a precise ratio. Concentrating and storing virus by ultracentrifugation is slow, harsh, and wastes titer. And many primary and suspension cells remain non-permissive to infection. At each step, we offer a dedicated solution: lipid-based reagents for production, magnetic and chemical solutions for capture and concentration, and magnetic, biochemical and on-column solutions to enhance transduction. ➡️ Looking to optimize your viral workflow? Explore full protocol and data on our website.

Efficient nucleic acid delivery starts with the right lipid. At OZ Biosciences, we've spent over 20 years developing lipid-based delivery systems. Building on this expertise, we've designed a library of more than 50 patented ionizable lipids: bioinspired, biodegradable, and optimized for LNP formulation. Our LNP platform supports all major nucleic acid types (mRNA, siRNA, sgRNA, DNA) and delivers robust expression in vitro, ex vivo, and in vivo. Organ selectivity (liver, spleen, or multi-organ distribution) is achieved through formulation optimization or targeting agents. Whether you're working on mRNA therapy, genome editing, vaccination, or CAR-T applications, our team can tailor a formulation to your specific model and requirements. Explore our LNP catalog or request a custom formulation: https://lnkd.in/du-krq9E